Protective effects of glucosamine-kynurenic acid after compression-induced spinal cord injury in the rat

Andrea Korimová, Dáša Cížková, J. Toldi, L. Vécsei, Ivo Vanický

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Kynurenic acid (KYNA), a metabolite of the essential amino acid L-tryptophan, is a broad spectrum antagonist of excitatory amino acid receptors, which have also anticonvulsant and neuroprotective properties. After spinal cord injury (SCI), excitotoxicity is considered to play a significant role in the processes of secondary tissue destruction in both grey and white matter of the spinal cord. In this study, we have tested the potential therapeutic effect of glucosamine-kynurenic acid, administered after experimental compression-induced SCI in the rat. Spinal application of glucosamine-kynurenic acid continually for 24 hr after experimental SCI resulted in improved motor function recovery, beginning from the first week of evaluation and continuing until the end of the study (4 weeks). After 4 weeks' survival, quantitative morphometric analysis of the spinal cord showed that glucosamine-kynurenic acid treatment was associated with improved tissue preservation at the lesion site. These findings indicate that spinal application of glucosaminekynurenic acid is neuroprotective and improves the outcome even when administered after spinal trauma. Our results suggest that the treatments initiated in early posttraumatic period can alleviate secondary injury and improve the final outcome after SCI.

Original languageEnglish
Pages (from-to)996-1004
Number of pages9
JournalCentral European Journal of Biology
Volume7
Issue number6
DOIs
Publication statusPublished - 2012

Fingerprint

Kynurenic Acid
glucosamine
Glucosamine
Spinal Cord Injuries
spinal cord
protective effect
Rats
Compaction
acids
rats
Spinal Cord
Tissue Preservation
Essential Amino Acids
Recovery of Function
Wounds and Injuries
Glutamate Receptors
Therapeutic Uses
Tryptophan
Anticonvulsants
Tissue

Keywords

  • Excitotoxicity
  • Kynurenic acid
  • NMDA receptor
  • Spinal cord injury

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Neuroscience(all)

Cite this

Protective effects of glucosamine-kynurenic acid after compression-induced spinal cord injury in the rat. / Korimová, Andrea; Cížková, Dáša; Toldi, J.; Vécsei, L.; Vanický, Ivo.

In: Central European Journal of Biology, Vol. 7, No. 6, 2012, p. 996-1004.

Research output: Contribution to journalArticle

@article{aaf079a65e9d4bb3b6a4a5697989ed53,
title = "Protective effects of glucosamine-kynurenic acid after compression-induced spinal cord injury in the rat",
abstract = "Kynurenic acid (KYNA), a metabolite of the essential amino acid L-tryptophan, is a broad spectrum antagonist of excitatory amino acid receptors, which have also anticonvulsant and neuroprotective properties. After spinal cord injury (SCI), excitotoxicity is considered to play a significant role in the processes of secondary tissue destruction in both grey and white matter of the spinal cord. In this study, we have tested the potential therapeutic effect of glucosamine-kynurenic acid, administered after experimental compression-induced SCI in the rat. Spinal application of glucosamine-kynurenic acid continually for 24 hr after experimental SCI resulted in improved motor function recovery, beginning from the first week of evaluation and continuing until the end of the study (4 weeks). After 4 weeks' survival, quantitative morphometric analysis of the spinal cord showed that glucosamine-kynurenic acid treatment was associated with improved tissue preservation at the lesion site. These findings indicate that spinal application of glucosaminekynurenic acid is neuroprotective and improves the outcome even when administered after spinal trauma. Our results suggest that the treatments initiated in early posttraumatic period can alleviate secondary injury and improve the final outcome after SCI.",
keywords = "Excitotoxicity, Kynurenic acid, NMDA receptor, Spinal cord injury",
author = "Andrea Korimov{\'a} and D{\'a}ša C{\'i}žkov{\'a} and J. Toldi and L. V{\'e}csei and Ivo Vanick{\'y}",
year = "2012",
doi = "10.2478/s11535-012-0096-2",
language = "English",
volume = "7",
pages = "996--1004",
journal = "Open Life Sciences",
issn = "1895-104X",
publisher = "Walter de Gruyter GmbH",
number = "6",

}

TY - JOUR

T1 - Protective effects of glucosamine-kynurenic acid after compression-induced spinal cord injury in the rat

AU - Korimová, Andrea

AU - Cížková, Dáša

AU - Toldi, J.

AU - Vécsei, L.

AU - Vanický, Ivo

PY - 2012

Y1 - 2012

N2 - Kynurenic acid (KYNA), a metabolite of the essential amino acid L-tryptophan, is a broad spectrum antagonist of excitatory amino acid receptors, which have also anticonvulsant and neuroprotective properties. After spinal cord injury (SCI), excitotoxicity is considered to play a significant role in the processes of secondary tissue destruction in both grey and white matter of the spinal cord. In this study, we have tested the potential therapeutic effect of glucosamine-kynurenic acid, administered after experimental compression-induced SCI in the rat. Spinal application of glucosamine-kynurenic acid continually for 24 hr after experimental SCI resulted in improved motor function recovery, beginning from the first week of evaluation and continuing until the end of the study (4 weeks). After 4 weeks' survival, quantitative morphometric analysis of the spinal cord showed that glucosamine-kynurenic acid treatment was associated with improved tissue preservation at the lesion site. These findings indicate that spinal application of glucosaminekynurenic acid is neuroprotective and improves the outcome even when administered after spinal trauma. Our results suggest that the treatments initiated in early posttraumatic period can alleviate secondary injury and improve the final outcome after SCI.

AB - Kynurenic acid (KYNA), a metabolite of the essential amino acid L-tryptophan, is a broad spectrum antagonist of excitatory amino acid receptors, which have also anticonvulsant and neuroprotective properties. After spinal cord injury (SCI), excitotoxicity is considered to play a significant role in the processes of secondary tissue destruction in both grey and white matter of the spinal cord. In this study, we have tested the potential therapeutic effect of glucosamine-kynurenic acid, administered after experimental compression-induced SCI in the rat. Spinal application of glucosamine-kynurenic acid continually for 24 hr after experimental SCI resulted in improved motor function recovery, beginning from the first week of evaluation and continuing until the end of the study (4 weeks). After 4 weeks' survival, quantitative morphometric analysis of the spinal cord showed that glucosamine-kynurenic acid treatment was associated with improved tissue preservation at the lesion site. These findings indicate that spinal application of glucosaminekynurenic acid is neuroprotective and improves the outcome even when administered after spinal trauma. Our results suggest that the treatments initiated in early posttraumatic period can alleviate secondary injury and improve the final outcome after SCI.

KW - Excitotoxicity

KW - Kynurenic acid

KW - NMDA receptor

KW - Spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=84867416797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867416797&partnerID=8YFLogxK

U2 - 10.2478/s11535-012-0096-2

DO - 10.2478/s11535-012-0096-2

M3 - Article

VL - 7

SP - 996

EP - 1004

JO - Open Life Sciences

JF - Open Life Sciences

SN - 1895-104X

IS - 6

ER -